Evidence map›Paper›PMID 34844601›Full record

ArticleBMC medicine2021

Marked reduction in antibiotic usage following intensive malaria control in a cohort of Ugandan children.

Paul J Krezanoski, Michelle E Roh, John Rek, Joaniter I Nankabirwa, Emmanuel Arinaitwe, Sarah G Staedke, Susan Nayiga, Michelle S Hsiang, David Smith, Moses Kamya and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Paul J KrezanoskiUniversity of California, 1001 Potrero Avenue, San Francisco, CA, 94118, USA. paul.krezanoski@ucsf.edu.ORCID 0000-0002-5376-5336
Michelle E RohUniversity of California, 1001 Potrero Avenue, San Francisco, CA, 94118, USA.
John RekInfectious Diseases Research Collaboration, Kampala, Uganda.
Joaniter I NankabirwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Emmanuel ArinaitweInfectious Diseases Research Collaboration, Kampala, Uganda.
Sarah G StaedkeLondon School of Hygiene and Tropical Medicine, London, UK.
Susan NayigaInfectious Diseases Research Collaboration, Kampala, Uganda.
Michelle S HsiangUniversity of California, 1001 Potrero Avenue, San Francisco, CA, 94118, USA.
David SmithUniversity of Washington, Seattle, WA, USA.
Moses KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Grant DorseyUniversity of California, 1001 Potrero Avenue, San Francisco, CA, 94118, USA.
Infectious Diseases Research Collaboration · UGPotrero Medical (United States) · USLondon School of Hygiene & Tropical Medicine · GBUniversity of Washington · US

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Identifying gaps between LLIN use and vector exposure to improve malaria controlK23AI139364 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KREZANOSKI, PAUL JOSEPH · 2019 to 2023
$986k
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS D43 TW010526FIC NIH HHS D43TW010526FIC NIH HHS K43 TW010365FIC NIH HHS K43TW010365NIAID NIH HHS K23 AI139364NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

backgroundIntensive malaria control may have additional benefits beyond reducing the incidence of symptomatic malaria. We compared antibiotic treatment of children before and after the implementation of highly effective malaria control interventions in Tororo, a historically high transmission area of Uganda.

methodsTwo successive cohorts of children, aged 0.5 to 10 years, were followed from September 2011 to October 2019 in a dedicated study clinic. Universal distribution of long-lasting insecticidal nets was conducted in 2013 and 2017. Sustained indoor residual spraying of insecticide (IRS) was initiated in December 2014. Generalized linear mixed-effects models were used to compare the incidence of antimalarial and antibiotic treatments before and after vector control measures were implemented.

resultsComparing the period prior to the implementation of IRS to the period after IRS had been sustained for 4-5 years, the adjusted incidence of malaria treatments decreased from 2.68 to 0.05 per person-year (incidence rate ratio [IRR] = 0.02, 95% CI 0.01-0.03, p < 0.001), and the adjusted incidence of antibiotic treatments decreased from 4.14 to 1.26 per person-year (IRR = 0.30, 95% CI 0.27-0.34, p < 0.001). The reduction in antibiotic usage was primarily associated with fewer episodes of symptomatic malaria and fewer episodes of fever with sub-microscopic parasitemia, both of which were frequently treated with antibiotics.

conclusionsIn a historically high transmission setting, the implementation of highly effective vector control interventions was followed by a marked reduction in antibiotic treatment of children. This added benefit of malaria control could have important implications for antibiotic prescribing practices, efforts to curtail antimicrobial resistance, and health system costs.

Indexed as

InsecticidesMalariaAnti-Bacterial AgentsChildHumansMosquito ControlUgandaAnti-Bacterial AgentsInsecticidesAntibiotic prescriptionsAntibiotic usageMalariaMalaria controlPediatric infectious diseasesPediatricsPrevention

Identifiers

PMID34844601
PMCPMC8630830
OpenAlexW3217006052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.